The U.S. Food and Drug Administration announced earlier today that denosumab, which will be marketed by Amgen under the brand name Xgeva, has been approved to help prevent fractures and to slow bone disease in patients with solid tumors. It was not approved at this time for use in patients with multiple myeloma.

“It wasn’t approved [for myeloma] because the Xgeva-treated subset of multiple myeloma patients had more deaths than the control arm,” said Erica Jefferson, a spokesperson for the Food and Drug Administration (FDA).

Xgeva is an antibody that prevents bone …

The U.S. Food and Drug Administration announced today that it approved Amgen’s Xgeva to help prevent fractures and to slow bone disease in patients with solid tumors that have spread to and caused damage to bone. Xgeva was not approved, however, for multiple myeloma patients with bone damage.

Xgeva is the new brand name given to denosumab when used for the treatment of cancer-related bone disease. Denosumab at lower doses is marketed under the brand name Prolia for the treatment of postmenopausal women with osteoporosis and a high risk of bone fractures. …

The pharmaceutical company Amgen recently announced that its new drug Prolia more effectively prevents bone pain and fractures in patients with advanced bone disease than Zometa. Prolia was noted to have higher efficacy in patients with various types of cancers, including multiple myeloma. The announcement followed the presentation of results from recent Phase 3 trials at the European Society of Medical Oncology Annual Meeting. 

Bone disease is frequently associated with multiple myeloma and can cause bone pain and lead to serious bone complications, such as lesions and fractures, …